Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124332 · ClinicalTrials.gov registry record · Phase 3
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
A Phase 3 study of Coronary Atherosclerosis, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
- 9
- Study locations
NCT00124332 is a Phase 3 study of Coronary Atherosclerosis that has completed, run by Sanofi. The registered enrollment target is 839 participants, above the 191-participant average among 5 other Coronary Atherosclerosis trials with a reported enrollment target (339% higher). The trial reports 9 study locations across 2 states.
The verdict
NCT00124332, a Phase 3 study of Coronary Atherosclerosis, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as needed, in patients with abdominal obesity associated with current smoking and/or metabolic syndrome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rimonabant (SR141716)
Study Locations (9)
Other
- sanofi-aventis, Australia - Macquarie Park
- sanofi-aventis, Belgium - Diegem
- Sanofi-Aventis Administrative Office - Laval
- sanofi-aventis, France - Paris
- sanofi-aventis Italy - Milan
- sanofi-aventis, Netherlands - Gouda
- sanofi-aventis Poland - Warsaw
- sanofi-aventis Spain - Barcelona
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124332
The ClinicalTrials.gov registry entry for NCT00124332 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 839 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 5 other Coronary Atherosclerosis trials with a reported enrollment target (339% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00124332 reports 9 study locations spanning 2 distinct geographic areas - top geographies include Other, Ohio.
Frequently Asked Questions
What is clinical trial NCT00124332 about?
NCT00124332 is a clinical study titled "STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)". The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as neede...
What is the current status of trial NCT00124332?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2005-01. Estimated completion is 2007-10.
What conditions does trial NCT00124332 study?
This clinical trial studies the following conditions: Coronary Atherosclerosis.
What interventions are being tested in trial NCT00124332?
The interventions under investigation include: Placebo (DRUG), Rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00124332?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00124332 being conducted?
This trial has 9 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
COMPLETED · Phase 3
-
Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
RECRUITING · NA
-
Using CTA Measures to Define Cardiac Risk In NFL Alumni
RECRUITING
-
Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)
COMPLETED · NA
-
Subclinical Atherosclerosis in HIV-infected Patients
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.